EBITDA: Income before interest, taxes, depreciation and amortization.
Viridian Therapeutics, Inc. (VRDN) had EBITDA of $-124.38M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$0.13M |
|
$-120.36M |
|
-- |
|
$0.13M |
|
$122.88M |
|
$-122.75M |
|
$2.39M |
|
$-120.36M |
|
$-120.36M |
|
$-120.36M |
|
$-120.36M |
|
$-120.36M |
|
$-120.36M |
|
$-122.75M |
|
|
EBITDA |
$-124.38M |
84.80M |
|
84.80M |
|
$-1.11 |
|
$-1.11 |
|
| Balance Sheet Financials | |
$894.23M |
|
$1.23M |
|
$5.18M |
|
$899.42M |
|
$70.70M |
|
$49.94M |
|
$106.56M |
|
$177.25M |
|
$590.11M |
|
$722.17M |
|
$722.17M |
|
101.83M |
|
| Cash Flow Statement Financials | |
$-276.39M |
|
$-37.56M |
|
$426.74M |
|
$99.59M |
|
$212.38M |
|
$112.79M |
|
$44.30M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
12.65 |
|
-- |
|
-- |
|
0.06 |
|
0.07 |
|
100.00% |
|
-92992.13% |
|
-92992.13% |
|
-- |
|
-91178.48% |
|
-91178.50% |
|
$-276.89M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-20.40% |
|
-16.67% |
|
-13.38% |
|
-15.59% |
|
$7.09 |
|
$-3.27 |
|
$-3.26 |
|